What is SK Biopharmaceuticals's contact information?

SK Biopharmaceuticals's contact information: +823180930114.

How many employees does SK Biopharmaceuticals have?

SK Biopharmaceuticals has 300 employees.

What industry does SK Biopharmaceuticals belong to?

SK Biopharmaceuticals is in the industry of: Pharmaceuticals, Biotechnology, Health Care.

What are SK Biopharmaceuticals's official social media profiles?

SK Biopharmaceuticals Linkedin Page SK Biopharmaceuticals Twitter Page

What are SK Biopharmaceuticals's office addresses?

SK Biopharmaceuticals has 2 known office addresses: 221, Pangyoyeok-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13494, KR 221, Pangyoyeok-ro, Bundang-gu, Seongnam, Gyeongsangbugdo, Kr, 13494.

What is SK Biopharmaceuticals's estimated annual revenue?

SK Biopharmaceuticals's revenue is $50,000,000

What is SK Biopharmaceuticals's open headcount?

SK Biopharmaceuticals has 48 job postings.

What is the number of ad campaigns for SK Biopharmaceuticals?

SK Biopharmaceuticals has no advertisements yet.

What is the number of recent news articles about SK Biopharmaceuticals?

SK Biopharmaceuticals has 64 news articles.

SK Biopharmaceuticals - Pubrio Company Profile & Intent

FREE TRIAL - NO CARD NEEDED

Close deals with the right data at the right time.

Pubrio gives your team the data, timing, and tools to reach the right prospects before the competition does.

Company & people search

Filter 560M+ contacts by role, industry, tech stack & more.

Sequences

Automate multi-step outreach without losing the personal touch.

Market signals

Stay ahead of every market shift. Pubrio Signals watches companies for you and delivers the right intelligence.

Start your free trial

Join 9,000+ revenue teams already using Pubrio.

No credit card · Cancel anytime · GDPR safe

Already have an account?Log in

SK Biopharmaceuticals

South Korea · Pharmaceuticals

Pharmaceuticals

Biotechnology

Health Care

SK Biopharmaceuticals is a part of the global conglomerate SK Group, the second largest company in Korea. We're responsible for the development of innovative next-generation drugs within SK Group. SK Biopharmaceuticals has been developing many new drug candidates in the area of CNS, led by the clinical development center(SK Life Science) located in United States and the research center in Pangyo Techno-valley, Gyeonggi-do. With the experience and expertise in the CNS area, SK Biopharmaceuticals will continue to thrive as a successful new drug development company and become a trusted partner through its global R&D network. By 2020, SK Biopharmaceuticals envisions to grow into a global Fully Integrated Pharmaceutical Company (FIPCO) with streamlined capabilities from research to marketing. For more information, visit our website at www.skbp.com.